Details of the Drug

General Information of Drug (ID: DMKAIR9)

Drug Name

AZD9574

Synonyms

AZD-9574; AZD9574; 2756333-39-6; 9UG32UQW48; UNII-9UG32UQW48; 2-Pyridinecarboxamide, 6-fluoro-5-(4-((5-fluoro-3,4-dihydro-2-methyl-3-oxo-6-quinoxalinyl)methyl)-1-piperazinyl)-N-methyl-; 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide; CHEMBL5095223; SCHEMBL24156588; GTPL11946; GLXC-25685; EX-A6177; NSC840950; AKOS040759967; AT34947; NSC-840950; example 20 [WO2021260092A1]; MS-27579; HY-145804; CS-0433406; 6-FLUORO-5-(4-((5-FLUORO-2-METHYL-3-OXO-3,4-DIHYDROQUINOXALIN-6-YL)METHYL)PIPERAZIN-1-YL)-N-METHYLPICOLINAMIDE

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H22F2N6O2
Canonical SMILES: CC1=NC2=C(C(=C(C=C2)CN3CCN(CC3)C4=C(N=C(C=C4)C(=O)NC)F)F)NC1=O
InChI: InChI=1S/C21H22F2N6O2/c1-12-20(30)27-18-14(25-12)4-3-13(17(18)22)11-28-7-9-29(10-8-28)16-6-5-15(21(31)24-2)26-19(16)23/h3-6H,7-11H2,1-2H3,(H,24,31)(H,27,30)
InChIKey: WXRCLFFPZXJCLS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 162524593
ChEBI ID: CHEMBL5095223
TTD ID: DC23ER

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Poly [ADP-ribose] polymerase (PARP)	TTEBCY8	NOUNIPROTAC	Inhibitor	[2]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05417594) A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of AstraZeneca